INVO Bioscience, Inc. (NASDAQ: INVO) shares were booming more than 107% to $6.44 in the pre-market session. Throughout the last five trading days, INVOstock has achieved a range of $3.00-$3.70. It has performed -6.61 percent during that period. Meanwhile, this stock has traded between $2.98 and $4.50 in the past month, changing by -10.89%. In the past three months, the stock has gained +0.43%, trading between $2.90 and $4.50.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
The company creates affordable medical devices and treatments that simplify the treatment process for patients with infertility. In vivo incubation provided by our solution, the INVO Procedure offers a more natural incubation experience for patients.
INVO Bioscience, Inc. (NASDAQ: INVO) announced on March 8, 2021, it had amended its exclusive U.S. commercialization agreement with Ferring Pharmaceuticals. An amendment to the agreement states that INVO company-owned clinics will be able to open a greater number of clinics initially allowed by the agreement.
The CEO of INVO Bioscience stock, Steve Shum, stated, We are pleased we were able to complete this amendment with our US partner, Ferring. Our shared aim of growing the use of INVOcell in the U.S. reflects the strength of our ongoing collaboration. Also, we believe that our dedicated clinic approach is an important channel in increasing awareness and market adoption. Hence, we believe that this strategy will increase industry capacity, raise consumer affordability and facilitate greater patient access. Our initial U.S. activities are expected to be reported in the future.
The amendment also adjusted the minimum annual contract purchase requirement for 2020 by Ferring, whereby INVO Bioscience, Inc. (NASDAQ: INVO)will generate $501,000 first-quarter revenue from the Ferring order.
An investor can expect a strong return on their biotech investment. Biotech companies take advantage of the latest scientific advances to discover medicines and treatments for a variety of illnesses, so they provide distinct opportunities for investors eager to earn profits.